000739.SHE Apeloa Pharmaceutical Co Ltd
- Market cap
- CNY 23.9B
- P/E
- 28.6x
- P/B
- 3.50x
- ROE
- 12.8%
- Dividend yield
- 3.41%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000739.SHE undervalued?
Graham number000739.SHE trades 111.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Apeloa Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Apeloa Pharmaceutical Co Ltd yet.
Apeloa Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&D and production services CDMO include R&D services, commercial human drug proje…
Full company profileApeloa Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Apeloa Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.77B | 5.55B | 6.38B | 7.21B | 7.88B | 8.94B | 10.5B | 11.5B | 12.0B | 9.76B | 9.11B |
| Gross Profit | 1.31B | 1.69B | 2.01B | 2.30B | 2.18B | 2.36B | 2.47B | 2.85B | 2.80B | 2.37B | 2.52B |
| Operating Income | 300M | 336M | 491M | 644M | 970M | 1.12B | 1.01B | 1.22B | 1.21B | 879M | 1.10B |
| EBITDA | 577M | 705M | 750M | 957M | 1.17B | 1.32B | 1.30B | 1.63B | 1.58B | 1.56B | 1.02B |
| Net Income | 263M | 257M | 371M | 553M | 817M | 956M | 989M | 1.06B | 1.03B | 891M | 818M |
| EPS | 0.23 | 0.22 | 0.31 | 0.47 | 0.69 | 0.81 | 0.85 | 0.90 | 0.89 | 0.77 | 0.71 |
| Balance Sheet | |||||||||||
| Total Assets | 5.62B | 5.69B | 5.75B | 6.52B | 7.49B | 9.04B | 12.0B | 12.8B | 12.7B | 12.3B | 12.3B |
| Total Liabilities | 3.00B | 2.64B | 2.41B | 2.75B | 3.10B | 3.98B | 6.50B | 6.54B | 5.98B | 5.97B | 5.87B |
| Shareholders' Equity | 2.62B | 3.05B | 3.35B | 3.77B | 4.39B | 5.06B | 5.51B | 6.22B | 6.74B | 6.34B | 6.40B |
| Cash & Short-term Investments | 553M | 551M | 746M | 1.50B | 2.31B | 2.62B | 3.55B | 3.58B | 3.66B | 3.79B | 3.38B |
| Total Debt | 1.20B | 1.11B | 686M | 122M | 330M | 460M | 828M | 831M | 898M | 1.51B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 180M | 210M | 833M | 1.36B | 1.06B | 612M | 1.33B | 1.03B | 1.21B | 1.23B | - |
| Capital Expenditure | 331M | 163M | 81.6M | 31.8M | 317M | 702M | 509M | 630M | 461M | 386M | 367M |
| Free Cash Flow | -151M | 46.4M | 751M | 1.33B | 742M | -90.2M | 817M | 401M | 748M | 844M | 533M |
| Ratios | |||||||||||
| ROE | 10.0% | 8.4% | 11.1% | 14.7% | 18.6% | 18.9% | 17.9% | 17.0% | 15.3% | 14.1% | 12.8% |
| ROA | 4.7% | 4.5% | 6.4% | 8.5% | 10.9% | 10.6% | 8.2% | 8.3% | 8.1% | 7.2% | 6.7% |
| Net Profit Margin | 5.5% | 4.6% | 5.8% | 7.7% | 10.4% | 10.7% | 9.4% | 9.2% | 8.6% | 9.1% | 9.0% |
| Debt to Equity | 0.46x | 0.36x | 0.21x | 0.03x | 0.08x | 0.09x | 0.15x | 0.13x | 0.13x | 0.24x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Apeloa Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.41%
- Forward dividend
- 0.38 CNY
- Payout ratio
- 91.2%
- Ex-dividend date
- Oct 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 812M | 0.70 | 91.2% |
| 2024 | CNY 402M | 0.35 | 39.0% |
| 2023 | CNY 383M | 0.33 | 36.3% |
| 2022 | CNY 336M | 0.29 | 34.0% |
| 2021 | CNY 286M | 0.24 | 30.0% |
| 2020 | CNY 201M | 0.17 | 24.7% |
| 2019 | CNY 130M | 0.11 | 23.4% |
| 2018 | CNY 120M | 0.10 | 32.3% |
| 2017 | CNY 142M | 0.12 | 55.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on May 30, 2014.
Who owns Apeloa Pharmaceutical Co Ltd
- Insiders 54.83%
- Institutions 9.08%
- Public & others 36.09%
- Shares outstanding 1.16B
- Free float 504M
Apeloa Pharmaceutical Co Ltd company profile
- Company name
- Apeloa Pharmaceutical Co Ltd
- Ticker
- 000739.SHE
- ISIN
- CNE000000Q45
- Exchange
- Shenzhen Stock Exchange
- Listed since
- May 9, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,787
- Fiscal year end
- December
- Address
- No.399 Jiangnan Road, Dongyang, China, 322118
- Phone
- 86 579 8655 7527
- Website
- apeloa.com
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&D and production services CDMO include R&D services, commercial human drug projects, commercial veterinary drug projects and other commercial projects; pharmaceutical business includes anti-infective, cardiovascular, psychotropic, hepatobiliary and anti-tumor categories. The company also provides technology platforms, such as flow chemistry, synthetic biology and biocatalysis, crystallization and particle engineering, peptide, high potency compound, conjugate library service, oligonucleotide synthesis, and preparation and purification; and controlled-release formulation development, taste masking technology, and particle flow simulation. In addition, it exports its products under the Tianliwei, Baishixin, Li'an, Jutai, and other brands. Apeloa Pharmaceutical Co.,Ltd was founded in 1989 and is based in Dongyang, the People's Republic of China.
Apeloa Pharmaceutical Co Ltd management
9- Mr. Fangmeng ZhuCEO & Chairman · born 1972
- Mr. Chun HePresident & Head of ACI BU · born 1974
- Mr. Min JinSenior Vice President · born 1968
- Mr. Lei CaiSenior Vice President & Head of CDMO BU · born 1979
- Mr. Yuwang ZhouVice President & Secretary · born 1966
- Mr. Lihua WuChief Financial Officer
- Mr. Hui ZhangChief Technology Officer
- Mr. Yonglong LiHead of API BU
- Mr. Liang YuHead of FDF BU